Literature DB >> 17988297

Chronic lymphoid leukaemia: clinico-haematological correlation and outcome in a single institution in Niger Delta region of Nigeria.

C E Omoti1, O A Awodu, G N Bazuaye.   

Abstract

Sixty patients were prospectively studied with the aim of analyzing the clinical and laboratory features and outcome of patients diagnosed with chronic lymphocytic leukaemia (CLL) in a major referral center in Niger Delta region of Nigeria for 10 years (1995-2005). The peripheral blood, bone marrow cytology, clinical features and stage at diagnosis were studied. Treatment modalities, response to treatment and survival outcome of the patients were analysed. Sixty patients (15 men and 45 women) were seen, with female preponderance (M : F ratio,1 : 3). The CLL incidence was 36.4% of total leukaemias. The median age was 56 years with peak age group at 51-60 years while 15% were below 40 years. Major clinical findings include lymphadenopathy (91.7%), anaemia (58.3%), abdominal swelling (58.3%), and splenomegaly (50%) with 53 patients (88.3%) presenting as International (Binet) stage B and C while only seven patients (11.7%) were seen in stage A. The least clinical presentation includes Richter's syndrome in 3.3% of cases and herpes Zoster skin manifestations in two patients (3.3%). There was a strong association between the blood counts at diagnosis and outcome of therapy. The 2-year survival for young (<55 years) and older (>55 years) CLL patients was 27.2% and 28.9%, respectively, which is still very poor because of a number of strong limiting factors. CLL is not rare in Southern Nigeria and its presentations are similar to cases seen worldwide. Contrary to existing literature a female predominance was observed in this study with majority of patients seeking medical intervention late. It is therefore recommended that future research into the genetic make up/HLA typing of patients of African descent is needed to clarify some of the differences observed.

Entities:  

Mesh:

Year:  2007        PMID: 17988297     DOI: 10.1111/j.1751-553X.2007.00888.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  11 in total

1.  Ethnic and geographic diversity of chronic lymphocytic leukaemia.

Authors:  Shenmiao Yang; Abraham M Varghese; Nitin Sood; Carlos Chiattone; Norah O Akinola; Xiaojun Huang; Robert Peter Gale
Journal:  Leukemia       Date:  2020-10-19       Impact factor: 11.528

2.  UK-based real-time lymphoproliferative disorder diagnostic service to improve the management of patients in Ghana.

Authors:  Elizabeth Parkins; Roger G Owen; George Bedu-Addo; Ohene Opare Sem; Ivy Ekem; Yvonne Adomakoh; Imelda Bates
Journal:  J Hematop       Date:  2009-07-09       Impact factor: 0.196

3.  Ophthalmic disorders in adult lymphoma patients in Africa.

Authors:  Afekhide E Omoti; Caroline E Omoti; Rita O Momoh
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

4.  Ocular disorders in adult leukemia patients in Nigeria.

Authors:  Afekhide E Omoti; Caroline E Omoti; Rita O Momoh
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

5.  Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience.

Authors:  Eiman A Al Zaabi; Louis A Fernandez; Irene A Sadek; D Christie Riddell; Wenda L Greer
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

6.  The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study.

Authors:  Caroline Edijana Omoti; Alexander Ikenna Nwannadi; Jude Chike Obieche; Adesuwa Noma Olu-Eddo
Journal:  Pan Afr Med J       Date:  2012-01-20

7.  Ophthalmic manifestations of acute and chronic leukemias presenting to a tertiary care center in India.

Authors:  Jacob Koshy; M Joseph John; Satish Thomas; Gurvinder Kaur; Nitin Batra; Wilson J Xavier
Journal:  Indian J Ophthalmol       Date:  2015-08       Impact factor: 1.848

8.  Mannose-binding lectin 2 (MBL2) gene polymorphisms do not influence frequency of infections in chronic lymphocytic leukemia patients.

Authors:  Katarina Holanda; Antonio Roberto Lucena-Araujo; Adônis Quintas; Taciana Mendonça; Aleide Lima; Luydson Richardson Vasconcelos; Patrícia Moura; Maria Cavalcanti; Cíntia Machado; Aderson Silva Araújo; Marcos Andre Bezerra
Journal:  Rev Bras Hematol Hemoter       Date:  2014

9.  Characteristics of chronic lymphocytic leukemia in Senegal.

Authors:  Abibatou Sall; Awa Oumar Touré; Fatimata Bintou Sall; Moussa Ndour; Seynabou Fall; Abdoulaye Sène; Blaise Félix Faye; Moussa Seck; Macoura Gadji; Tandakha Ndiaye Dièye; Claire Mathiot; Sophie Reynaud; Saliou Diop; Martine Raphaël
Journal:  BMC Hematol       Date:  2016-04-23

10.  The impact of immune checkpoint inhibitors in patients with chronic lymphocytic leukemia (CLL): A protocol for a systematic review and meta-analysis of randomized controlled trials.

Authors:  Aviwe Ntsethe; Phiwayinkosi Vusi Dludla; Tawanda Maurice Nyambuya; Siphamandla Raphael Ngcobo; Bongani Brian Nkambule
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.